Podcast
Questions and Answers
What is the underlying genetic cause of Duchenne muscular dystrophy (DMD)?
What is the underlying genetic cause of Duchenne muscular dystrophy (DMD)?
- Mutation in the actin gene
- Mutation in the myosin gene
- Mutation in the troponin gene
- Mutation in the dystrophin gene (correct)
How does antisense therapy like Eteplirsen work to treat DMD?
How does antisense therapy like Eteplirsen work to treat DMD?
- By binding to dystrophin protein directly
- By binding to pre-mRNA to alter splicing (correct)
- By neutralizing the effect of dystrophin mutations
- By enhancing the function of dystrophin protein
Which physiological consequence results from the loss of dystrophin function in muscle fibers?
Which physiological consequence results from the loss of dystrophin function in muscle fibers?
- Inhibition of muscle fibers necrosis
- Enhanced muscle regeneration capabilities
- Attachment failure of the cytoskeleton to the sarcolemma (correct)
- Increased muscle contractility
What is the ultimate consequence of muscle degeneration in DMD patients?
What is the ultimate consequence of muscle degeneration in DMD patients?
What type of drug is Eteplirsen considered in the context of DMD treatment?
What type of drug is Eteplirsen considered in the context of DMD treatment?
How do cholinergic agonists differ from cholinergic antagonists?
How do cholinergic agonists differ from cholinergic antagonists?
What happens to the action potential in muscle fibers when neuromuscular blocking agents (NMBAs) are used?
What happens to the action potential in muscle fibers when neuromuscular blocking agents (NMBAs) are used?
In the context of myasthenia gravis (MG), which statement correctly relates clinical manifestation to muscle physiology?
In the context of myasthenia gravis (MG), which statement correctly relates clinical manifestation to muscle physiology?
What is the main therapeutic goal of Eteplirsen in the treatment of Duchenne muscular dystrophy?
What is the main therapeutic goal of Eteplirsen in the treatment of Duchenne muscular dystrophy?
Which of the following is NOT a reversible acetylcholinesterase inhibitor?
Which of the following is NOT a reversible acetylcholinesterase inhibitor?
What adverse effect is commonly associated with the use of physostigmine?
What adverse effect is commonly associated with the use of physostigmine?
What differentiates non-depolarizing neuromuscular blocking agents from depolarizing agents?
What differentiates non-depolarizing neuromuscular blocking agents from depolarizing agents?
How does edrophonium contribute to the diagnosis of Myasthenia Gravis?
How does edrophonium contribute to the diagnosis of Myasthenia Gravis?
What is the primary mechanism of action for acetylcholinesterase inhibitors?
What is the primary mechanism of action for acetylcholinesterase inhibitors?
Which of the following statements about neostigmine is correct?
Which of the following statements about neostigmine is correct?
Which type of drug binds to cholinoceptors and prevents the effects of acetylcholine?
Which type of drug binds to cholinoceptors and prevents the effects of acetylcholine?
What is the clinical significance of succinylcholine?
What is the clinical significance of succinylcholine?
Which acetylcholinesterase inhibitor has the shortest duration of action?
Which acetylcholinesterase inhibitor has the shortest duration of action?
What condition may lead to generalized cholinergic stimulation when using acetylcholinesterase inhibitors?
What condition may lead to generalized cholinergic stimulation when using acetylcholinesterase inhibitors?
Which of the following is a feature of non-depolarizing neuromuscular blocking agents?
Which of the following is a feature of non-depolarizing neuromuscular blocking agents?
What happens during Phase II of succinylcholine action?
What happens during Phase II of succinylcholine action?
Flashcards are hidden until you start studying
Study Notes
Duchenne Muscular Dystrophy (DMD)
- DMD is caused by a mutation in the dystrophin gene (recessive and x-linked)
- Dystrophin connects the cytoskeleton to the sarcolemma
- Loss of dystrophin leads to muscle fiber necrosis and wasting
- Respiratory muscle failure is a leading cause of death in DMD patients
Eteplirsen for DMD Treatment
- Antisense therapy targets pre-mRNA of dystrophin to rearrange splicing and produce more dystrophin
- This results in more functional dystrophin being present
- Goal is to slow or prevent the progression of DMD
Cholinergic Agonists and Antagonists
- Indirect-acting cholinergic agonists (anticholinesterase agents) inhibit acetylcholinesterase (AChE)
- AChE degrades acetylcholine (ACh), so inhibiting it leads to ACh accumulation and increased signaling
- Reversible AChE inhibitors can be categorized as short-, intermediate-, or long-acting
- Edrophonium: short-acting, rapid absorption, short duration of action, used to diagnose myasthenia gravis (MG)
- Physostigmine: intermediate-acting, forms a stable intermediate with AChE, used to manage symptoms of MG
- Neostigmine: reversibly inhibits AChE, long-acting, has a similar duration of action to physostigmine, used to manage symptoms of MG
Myasthenia Gravis (MG)
- Autoimmune condition affecting the neuromuscular junction (NMJ)
- Antibodies against nicotinic acetylcholine receptors interfere with signaling
- Symptoms include varying muscle weakness
- Treatment includes anticholinesterase inhibitors
Cholinergic Antagonists
- Block the effects of acetylcholine (ACh) at muscarinic or nicotinic receptors
- Used to treat various conditions
- Include antimuscarinic agents, ganglionic blockers, and neuromuscular-blocking agents (NMBAs)
Neuromuscular Blocking Agents (NMBAs)
- Block cholinergic transmission between motor nerve endings and the nicotinic receptors on skeletal muscle
- NMJ blockers are useful during surgery
- Non-depolarizing agents (e.g., pancuronium, vecuronium, rocuronium) act as competitive antagonists at the nicotinic receptor
- Depolarizing agents (e.g., succinylcholine) act as agonists at the nicotinic receptor, causing initial depolarization and subsequent resistance to further stimulation
Non-Depolarizing NMBAs
- Pancuronium: long-acting
- Vecuronium: short-acting
- Rocuronium: shortest-acting
Depolarizing NMBAs
- Succinylcholine: rapid onset, short-acting, resistant to AChE
- Overall, the lecture covers the pharmacology of skeletal muscle, specifically focusing on drugs that target the NMJ. It explores the mechanisms of action of various medications used to treat DMD, MG, and muscle paralysis during procedures.*
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.
